483
Danny Rischin, MBBS, FRACP, MDFDA 483 - Danny Rischin, MBBS, FRACP, MD - September 18, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Danny Rischin, MBBS, FRACP, MD, a clinical investigator in Melbourne, Australia, revealed significant issues with clinical trial data integrity and protocol adherence. The firm failed to accurately report case histories, including adverse events and concomitant medications, and did not conduct investigations in accordance with the study protocol, specifically regarding required radiologic imaging timepoints.
Open in Dashboard
ID · 3d3dc856-a3e8-4e18-9499-fb99d1a2d1ee